Nerante Numbing Cream

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the temporary relief of local and anorectal itching and discomfort associated with anorectal disorders. It is also indicated for the temporary relief of pain, burning, and soreness in the anorectal area.

Limitations of Use: This drug is intended for short-term use and should not be used as a substitute for comprehensive treatment of underlying anorectal conditions.

Dosage and Administration

For adults and children aged 12 years and older, it is recommended that the application site be cleaned with mild soap and warm water, followed by thorough rinsing. The area should then be gently dried by patting or blotting with toilet tissue or a soft cloth prior to application. The product may be applied up to six times daily.

For children under 12 years of age, consultation with a healthcare professional is advised before use.

Contraindications

Use is contraindicated in the following situations:

Application on broken or irritated skin is prohibited due to the potential for exacerbating the condition and causing further irritation. Additionally, insertion into the rectum with fingers, mechanical devices, or applicators is contraindicated to prevent injury or adverse effects.

Warnings and Precautions

For external use only. It is imperative to keep this product out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact a Poison Control Center without delay.

This product should not be applied to broken or irritated skin. Healthcare professionals are advised to instruct patients to discontinue use and consult a physician if any of the following occur: an allergic reaction is observed; symptoms such as redness, irritation, swelling, or pain begin or worsen; or if there is no noticeable improvement within 7 days of application.

Side Effects

Patients using this product should be aware that it is intended for external use only. In clinical practice, some participants have reported adverse reactions that necessitate caution.

Serious adverse reactions may include allergic reactions, which can manifest as symptoms such as redness, irritation, swelling, or pain. If any of these symptoms begin or worsen, it is advised that patients discontinue use immediately.

Additionally, if there is no improvement in the condition being treated within 7 days of use, patients should also stop using the product and consult a healthcare professional. These recommendations are based on both clinical trial data and postmarketing experiences, emphasizing the importance of monitoring for any adverse effects during treatment.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Nerante Numbing Cream (lidocaine hcl). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 12 years and older may apply the medication up to 6 times daily. For children under 12 years of age, it is advised to consult a doctor before use.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

The safety of NERANTE Numbing Cream (lidocaine hcl cream) during pregnancy has not been established. There may be potential risks to the fetus; therefore, it is essential for pregnant patients to consult a healthcare provider before use. Dosage adjustments may be necessary for pregnant individuals, and medical advice should be sought to determine the appropriate course of action. NERANTE Numbing Cream should be used only if clearly needed and after thorough discussion with a healthcare professional to weigh the benefits against any potential risks.

Lactation

There are no specific warnings or recommendations regarding the use of NERANTE Numbing Cream in lactating mothers. Additionally, there is no information available concerning the potential for excretion of the product in breast milk or any associated risks to breastfed infants.

Renal Impairment

Patients with renal impairment may require dosage adjustments to ensure safety and efficacy. It is essential to monitor renal function tests in individuals with kidney problems to assess their renal status. Additionally, a reduced dose should be considered for patients with decreased creatinine clearance to mitigate the risk of adverse effects associated with impaired renal function.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in clinical trials for this medication. Consequently, there is no available information regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be warranted based on clinical judgment.

Overdosage

There is currently no specific information available regarding overdosage for this medication. Healthcare professionals are advised to monitor patients closely for any signs of adverse effects or symptoms that may arise from excessive dosing.

In the event of suspected overdosage, it is recommended that healthcare providers initiate supportive care and symptomatic treatment as necessary. Patients should be evaluated for potential complications, and appropriate interventions should be implemented based on clinical judgment.

For further guidance, healthcare professionals may refer to established protocols for managing drug overdosage or consult a poison control center.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

Postmarketing experience has identified cases of allergic reactions associated with the use of the product. Symptoms reported include redness, irritation, swelling, and pain, which may begin or worsen following administration. In instances where these symptoms do not show improvement within 7 days, further evaluation may be warranted.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children and to seek immediate medical assistance or contact a Poison Control Center if the medication is swallowed. Patients should be instructed not to use the product on broken or irritated skin to avoid potential complications.

It is important for healthcare providers to inform patients about the possibility of allergic reactions. Patients should be made aware to discontinue use and seek medical attention if they experience symptoms such as redness, irritation, swelling, pain, or if any other adverse effects begin or worsen.

Patients should be counseled that if there is no improvement in their condition within 7 days of use, they should consult their healthcare provider for further evaluation. Additionally, they should be advised to use only the amount of the medication that is recommended, unless otherwise directed by a healthcare professional.

Finally, healthcare providers should emphasize that the medication should not be inserted into the rectum using fingers, mechanical devices, or applicators to ensure safe and appropriate use.

Storage and Handling

The product is supplied in a tube that must be kept tightly closed when not in use to maintain its integrity. It should be stored at room temperature, away from direct light to protect its formulation. Once opened, the product should be discarded to ensure safety and efficacy.

Additional Clinical Information

The product is administered topically, with a recommended application frequency of up to six times daily. Clinicians should advise patients not to apply the product on broken or irritated skin and to avoid inserting it into the rectum using fingers or any mechanical devices or applicators.

Patients should be informed of potential allergic reactions, which may manifest as redness, irritation, swelling, or pain, and to discontinue use if these symptoms begin or worsen. If there is no improvement within seven days, patients should seek further medical advice. Additionally, the product should be kept out of reach of children, and in the event of ingestion, medical assistance or contact with a Poison Control Center is necessary.

Drug Information (PDF)

This file contains official product information for Nerante Numbing Cream, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)